GlassScriptPhysician profile
Jeffery Oka
NPI 1528194826
$1,739.60
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.75 · 2020: $349 · 2021: $321 · 2022: $377 · 2023: $351 · 2024: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $180.45 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $152.46 | 2020-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $145.93 | 2020-2024 | Mounjaro, Jardiance, Trulicity |
| Janssen Pharmaceuticals, INC | $129.26 | 2020-2022 | |
| Pfizer INC. | $128.68 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $105.71 | 2019-2022 | |
| Novo Nordisk INC | $74.19 | 2020-2022 | |
| Glaxosmithkline, LLC. | $71.56 | 2020-2024 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $67.11 | 2022-2024 | Rexulti |
| Abbvie INC. | $63.09 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.58 | 2021-2023 | |
| Daiichi Sankyo INC. | $55.86 | 2023-2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $45.87 | 2022 | |
| Corcept Therapeutics | $43.79 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $42.94 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $38.44 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $37.52 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.68 | 2023 | Rexulti |
| Arbor Pharmaceuticals, INC. | $29.56 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $27.85 | 2023 | Rytary |
| Edwards Lifesciences Corporation | $22.88 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Mylan Specialty L.P. | $21.61 | 2020 | |
| Grifols USA, LLC | $20.60 | 2024 | Prolastin-C Liquid |
| Horizon Therapeutics Plc | $19.75 | 2021 | |
| Eisai INC. | $14.71 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.61 | 2024 | Voquezna |
| Currax Pharmaceuticals LLC | $14.19 | 2023 | Contrave |
| Sanofi Pasteur INC. | $13.49 | 2023 | |
| Ascensia Diabetes Care US INC. | $13.30 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.07 | 2023 | |
| Nestle Healthcare Nutrition INC. | $12.82 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.38 | 2022 | |
| Sumitomo Pharma America, INC. | $11.66 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Oka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.